Product category |
|
Therapeutic indication |
|
Dosing |
|
Efficacy |
|
Key features |
|
Challenges |
Quantitative testing for glucose-6-phosphate dehydrogenase (G6PD) deficiency required, as contraindicated in G6PD deficiency No quantitative G6PD test has been prequalified or approved by a stringent regulatory agency yet
|
Status |
Approved by US FDA July 2018 and by Australian TGA September 2018 Approved in first malaria-endemic country (Brazil) in October 2019 and in Thailand in December 2019 Under review in 5 endemic countries
|
Next milestone |
Pharmacokinetic results expected for the INSPECTOR study, assessing safety and efficacy of TQ in combination with DHA-PQP Start of feasibility study in Brazil and in Thailand, in conjunction with quantitative G6PD testing
|
MMV Project Director |
|